IP Library Granted Patent US 12679877
Granted Patent B2
US 12679877 · App. 16/577,947 · Granted Jul 14, 2026

NPRA agonists, compositions, and uses thereof

Inventors: Gerardo M. Castillo (Bothell, WA); Akiko Nishimoto-Ashfield (Bothell, WA); Elijah M. Bolotin (Bothell, WA)
Assignee: PharmaIN Corporation
C07K14/575A61K47/542A61P9/00A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12679877
App. No.
16/577,947
Granted
Jul 14, 2026
Kind
B2
Abstract

This disclosure provides a natriuretic peptide derivative of Formula (I), and to compositions including a natriuretic peptide derivative of Formula (I), (fatty acyl) z -(B) x -(G) y -NP   (I), wherein: z is 1, x is an integer from 2 to 4 and y is 3; or z is 0, x is an integer from 0 to 4 and y is an integer from 1 to 3; fatty acyl comprises from 12 to 24 (e.g., 12 to 18) carbons atoms; B is lysine or arginine; G is glycine; NP is a natriuretic peptide; if present, (fatty acyl) z - is covalently linked to the N-terminus of (B) x ; (fatty acyl) z -(B) x — is covalently linked to the N-terminus of (G) y ; and (fatty acyl) z -(B) x -(G) y - is covalently linked to the N-terminus of NP. The natriuretic peptide derivative according to the disclosure, and compositions thereof, are useful in the treatment of diseases such as hypertension, vascular congestion, and heart disease.

Claims (7)

1 . A composition comprising a natriuretic peptide derivative, wherein the natriuretic peptide derivative comprises SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 52, SEQ ID NO: 56, SEQ ID NO: 68, SEQ ID NO: 72, SEQ ID NO: 86, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 113, or SEQ ID NO: 122.

2 . The composition according to claim 1 , wherein the natriuretic peptide derivative is selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 56, SEQ ID NO: 52, SEQ ID NO: 113, SEQ ID NO: 68, SEQ ID NO: 122, and SEQ ID NO: 72.

3 . The composition according to claim 1 , wherein the natriuretic peptide derivative is selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 56, and SEQ ID NO: 72.

4 . The composition according to claim 1 , wherein the natriuretic peptide derivative is selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 56, SEQ ID NO: 52, SEQ ID NO: 68, SEQ ID NO: 122, and SEQ ID NO: 72.

5 . The composition according to claim 1 , further comprising an excipient.

6 . The composition of claim 1 , wherein the natriuretic peptide derivative is, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 52, SEQ ID NO: 56, SEQ ID NO: 68, SEQ ID NO: 72, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 113, or SEQ ID NO: 122.

7 . A method of increasing blood cGMP in a patient, the method comprising parenterally administering to the patient a composition according to claim 1 .